Targeting the atherosclerotic process in clinical practice. A new look at established agents

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Circulation·2026

Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

The lancet. Diabetes & endocrinology·2026

Effect of statins and ACE inhibitors on the metabolome in the Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT) cohort.

Scientific reports·2026

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA cardiology·2026

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

JAMA internal medicine·2026

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

Diabetes care·2025

The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion.

Atherosclerosis·2026

Ultrasound-detected fatty liver in young adults and long-term risk of atherosclerotic cardiovascular disease: The Young Finns Study.

Atherosclerosis·2026

Impact of saturated fat absorption on serum low density lipoprotein-cholesterol response to the replacement of saturated with unsaturated fats in healthy males. The 'Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention-2 (RISSCI-2)' non-randomised sequential dietary intervention study.

Atherosclerosis·2026

Mapping the modifiable exposome for ischemic stroke: association, causality, and preventive potential.

Atherosclerosis·2026

Transcriptomic profiling identifies tumor necrosis factor receptor-associated factor (TRAF)-5 expression in human atherosclerotic plaques as a predictor of future cardiovascular events.

Atherosclerosis·2026

Effect of in-hospital initiation of alirocumab on clinical outcomes in Chinese ACS patients: findings from the Chinese Cardiovascular Association (CCA) Database-Chest Pain Center.

Atherosclerosis·2026

Targeting CKIP-1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential.

Cell proliferation·2026

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

Acta biomaterialia·2026

Cardio-renal protection of MRAs in kidney-transplanted diabetic patients.

Pharmacological research·2026

Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.

ACS chemical biology·2026

Related Experiment Videos

Targeting the atherosclerotic process in clinical practice. A new look at established agents

Related Concept Videos

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.

Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.

Effect of statins and ACE inhibitors on the metabolome in the Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT) cohort.

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretion.

Ultrasound-detected fatty liver in young adults and long-term risk of atherosclerotic cardiovascular disease: The Young Finns Study.

Impact of saturated fat absorption on serum low density lipoprotein-cholesterol response to the replacement of saturated with unsaturated fats in healthy males. The 'Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention-2 (RISSCI-2)' non-randomised sequential dietary intervention study.

Mapping the modifiable exposome for ischemic stroke: association, causality, and preventive potential.

Transcriptomic profiling identifies tumor necrosis factor receptor-associated factor (TRAF)-5 expression in human atherosclerotic plaques as a predictor of future cardiovascular events.

Effect of in-hospital initiation of alirocumab on clinical outcomes in Chinese ACS patients: findings from the Chinese Cardiovascular Association (CCA) Database-Chest Pain Center.

Targeting CKIP-1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential.

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

Cardio-renal protection of MRAs in kidney-transplanted diabetic patients.

Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.

Related Experiment Videos

Targeting the atherosclerotic process in clinical practice. A new look at established agents

Related Concept Videos

Related Articles